用甲氨蝶呤治疗癌症

{"title":"用甲氨蝶呤治疗癌症","authors":"","doi":"10.33140/mcr.06.02.04","DOIUrl":null,"url":null,"abstract":"As new anticancer agents are tried cancer treatment, the author remembered complete remission of choriocarcinoma and metastases with methotrexate (MTX) administered within some months, to get normal uterine pregnancy and usual life, thus wondered non-sergical MTX treatment of human common cancer, and several cancer treatments in Pubmed and NIH reports with success. The amount of chorioarcinoma therapy by MTX was 0.45 mg / kg /day, 200mg in a week, inserting some days’ rest, and repeated some months to get the full necrosis of uterine primary focus and metastases in my complete remission.","PeriodicalId":9304,"journal":{"name":"British Medical Journal (Clinical research ed.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cancer Treatment with Per Os Administered Methotrexate\",\"authors\":\"\",\"doi\":\"10.33140/mcr.06.02.04\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"As new anticancer agents are tried cancer treatment, the author remembered complete remission of choriocarcinoma and metastases with methotrexate (MTX) administered within some months, to get normal uterine pregnancy and usual life, thus wondered non-sergical MTX treatment of human common cancer, and several cancer treatments in Pubmed and NIH reports with success. The amount of chorioarcinoma therapy by MTX was 0.45 mg / kg /day, 200mg in a week, inserting some days’ rest, and repeated some months to get the full necrosis of uterine primary focus and metastases in my complete remission.\",\"PeriodicalId\":9304,\"journal\":{\"name\":\"British Medical Journal (Clinical research ed.)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Medical Journal (Clinical research ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33140/mcr.06.02.04\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Medical Journal (Clinical research ed.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/mcr.06.02.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

随着新的抗癌药物在癌症治疗中的尝试,作者记得绒毛膜癌和转移瘤在几个月内使用甲氨蝶呤(MTX)完全缓解,获得正常子宫妊娠和正常生活,因此对人类常见癌症的非手术MTX治疗感到惊讶,Pubmed和NIH报道的几种癌症治疗都取得了成功。甲氨蝶呤治疗绒毛膜癌的剂量为0.45 mg / kg /天,每周200mg,中间休息几天,重复几个月,直至子宫原发灶完全坏死,转移完全缓解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cancer Treatment with Per Os Administered Methotrexate
As new anticancer agents are tried cancer treatment, the author remembered complete remission of choriocarcinoma and metastases with methotrexate (MTX) administered within some months, to get normal uterine pregnancy and usual life, thus wondered non-sergical MTX treatment of human common cancer, and several cancer treatments in Pubmed and NIH reports with success. The amount of chorioarcinoma therapy by MTX was 0.45 mg / kg /day, 200mg in a week, inserting some days’ rest, and repeated some months to get the full necrosis of uterine primary focus and metastases in my complete remission.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信